Center for Breakthrough Medicines and BioAnalysis Form Alliance

The Center for Breakthrough Medicines (CBM) has entered into an agreement with BioAnalysis LLC (BIA) to provide CBM’s clients with direct access to BIA’s advanced testing capabilities, including characterization of viral vectors using BIA’s proprietary sedimentation velocity approach to analytical ultracentrification (SV-AUC), as well as other advanced biophysical methods and analytics.

Dr. Lake Paul, founder and principal scientist at BIA, is regarded as a leader in the field and is frequently engaged to conduct rigorous evaluation of gene therapy products and processes.  Through this alliance, CBM gains the expert scientific and data analysis provided by Dr. Paul and his team, an invaluable resource for CBM clients in need of sophisticated assay and method development and a trusted cGMP-compliant laboratory for characterization and advanced analytical methods. 

Dana Cipriano, senior vice president of testing and analytical services at CBM, said, “We could not be more delighted to partner with Dr. Paul and the BIA team—the next generation testing capabilities they bring to the table for CBM’s innovator clients will be a game-changer.

“As a CDMO collaborator, BIA has found the perfect match in CBM,” says Dr. Paul, adding “Our testing capabilities are unrivaled, and the sophisticated innovator clientele CBM connects with BIA will be a true differentiator in the CGT analytical testing space.”